Japan's oldest person dies at 114
Hiroyasu, from the city of Nakatsu in Oita Prefecture, was born in January 1911.
She became the oldest living person in Japan in May this year, following the death of another 114-year-old woman from the town of Oyama, Shizuoka Prefecture.
The cause of Hiroyasu's death has not been disclosed.
Shigeko Kagawa, a 114-year-old resident of Yamatokoriyama, a city in Nara Prefecture, is now the oldest living person in the country. She was born in May 1911.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Times
an hour ago
- Japan Times
Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's
Sumitomo Pharma said Tuesday it is seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain, following a successful clinical trial. The drugmaker applied to Japanese regulators for manufacturing and marketing authorization aimed at treating patients with advanced Parkinson's disease, it said in a statement. A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells — which have the potential to develop into any cell in the body — was safe and successful in improving symptoms. The study involved seven Parkinson's patients between 50 and 69 years old, with each receiving a total of either 5 million or 10 million cells implanted on both sides of the brain. The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease. The patients were monitored for two years, and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said. The trial results were published in Nature in April. Sumitomo Pharma is also carrying out a clinical trial in the United States. Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement. Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation. Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation said. iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state — basically cloning without the need for an embryo. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
Japan Times
7 hours ago
- Japan Times
Kyoto University team develops pain reliever comparable to morphine
A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects. Morphine, often administered to cancer patients, has serious adverse effects such as breathing issues and addiction. According to the team, the newly developed drug, Adriana, is a groundbreaking painkiller, which works on a completely different mechanism to morphine and other existing synthetic opioids. The drug has the potential to revolutionize pain control in the medical field, the team said. The team also expects that the drug will help resolve the so-called opioid epidemic, in which a large number of deaths occur mainly due to overdoses of opioids. Its findings were published in the online edition of the U.S. journal Proceedings of the National Academy of Sciences. When a person encounters a life-threatening situation, norepinephrine, an organic chemical secreted from the brain, suppresses pain. For its study, the team focused on the human body regulating oversecretion of norepinephrine. By introducing a new research technology, the team succeeded in developing a drug blocking such a control function for the first time in the world. In a clinical trial conducted at the Kyoto University Hospital between January 2023 and December 2024, the team confirmed the new drug's efficiency to a certain extent for patients including 20 who underwent lung cancer surgery. The team plans to conduct a clinical trial in the United States for 400 postsurgery patients in 2026, aiming to put Adriana into practical use in 2028. "We hope that the new drug will help cancer patients who previously had no choice but to use opioids live their lives without pain as well as a need to worry about addiction or serious side effects," Masatoshi Hagiwara, a professor at the university, said.
Japan Times
2 days ago
- Japan Times
Kobayashi Pharmaceutical chairman vows corporate culture reform
Japan's Kobayashi Pharmaceutical will accelerate efforts to reform its corporate culture marked by workers' reliance on top management, Chairman Yoshihito Ota has said. A major problem the drug and supplement maker must address is the "strong tendency to depend on top management," seen among its employees, Ota said in a recent interview. Ota took office in March after being invited from outside the Osaka-based company, following a massive health hazard caused by supplements containing beni kо̄ji red yeast rice ingredients that came to light early last year. Led by top executives mainly from the founding family, Kobayashi Pharmaceutical achieved net profit growth for over 20 years from its stock market listing in 1999, until the beni kо̄ji scandal emerged. For many employees, "it was easier to work if they depended on someone rather than asserting themselves" during the period of strong growth, Ota said. As the company focused on generating profits, capital investment plans were often delayed, leaving the manufacturing staff exhausted, but the division did not request an improvement, according to Ota. "The manufacturing division weakened," while the marketing division was strong, he continued. Probes into the beni kо̄ji scandal have found that culture drums in a company factory had cracks due to aging, indicating the possibility that mold spores may have entered the drums through the cracks, allowing the substance that caused the health hazard to generate inside the drums. "It's best to renew facilities systematically," Ota said, underscoring his intent to strengthen the manufacturing division. Saying that quality control has not been unified across the entire group, Ota also emphasized, "We'll carry out structural reform of the entire manufacturing division." Before joining Kobayashi Pharmaceutical, Ota was involved in the reconstruction of Japan Airlines after its 2010 bankruptcy, as a close aide to the late Kyocera founder Kazuo Inamori, who led the airlines' turnaround. Under Ota, Kobayashi Pharmaceutical regularly holds a leadership workshop for senior officials to foster a culture where employees make decisions and take action independently. "The corporate culture will not change unless the older generation changes, " he said.
